Table 2.
TPRs in ovarian, uterine, cervical and vaginal tissue
| Cervix TPR | Ovary TPR | Uterus TPR | Vagina TPR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug | Median (IQR) | n | P | Median (IQR) | n | P | Median (IQR) | n | P | Median (IQR) | n | P |
| Tenofovir | 1.22 (0.77–1.96) | 15 | ref | 1.21 (0.88–1.89) | 14 | 0.95 | 1.14 (0.65–2.91) | 15 | 0.41 | 1.86 (1.31–5.54) | 16 | 0.03 |
| Lamivudine | 1.24 (0.98–1.67) | 21 | ref | 1.34 (0.97–1.72) | 19 | 0.81 | 1.05 (0.94–1.63) | 21 | 0.36 | 1.83 (1.11–2.92) | 22 | 0.001 |
| Efavirenz | 0.51 (0.22–0.82) | 12 | ref | 0.65 (0.24–1.23) | 10 | 0.01 | 0.51 (0.35–0.88) | 12 | 0.04 | 0.59 (0.28–0.7) | 13 | 0.02 |
| Fluconazole | 0.92 (0.90–0.96) | 13 | ref | 0.85 (0.64–0.94) | 12 | 1 | 0.89 (0.86–0.94) | 14 | 0.69 | 0.94 (0.87–1.10) | 14 | 0.017 |
Values of n are the sample size and P values are from the Wilcoxon test between the other FGT tissues and the cervical tissue (indicated as ‘ref’).